NovoCure Limited
NovoCure Limited (NVCR) PE Ratio — Current & Historical Data
Trailing twelve months (TTM) P/E, forward P/E, PEG, and annual PE history — from market prices and filings.
nvcr · pe ratio · data through Dec 31, 2025
Core PE Ratio Metrics
Trailing 12 months · TTMThe price-to-earnings (P/E) ratio for NovoCure Limited (NVCR) measures how much investors pay for each dollar of the company's trailing earnings. NVCR's current PE ratio of N/A is calculated by dividing its stock price of $17.43 by its TTM earnings per share of -$1.52.
Source: FMP · /ratios-ttm · /analyst-estimates · 2025-12-31
PE Ratio History
2013 – 2025 · Annual▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare (Annual)
PE Ratio vs Peers
Medical - Instruments & Supplies · 6 peers · Annual PE| Company | Market Cap | PE (Annual) | vs Avg | EPS (TTM) |
|---|---|---|---|---|
NovoCure LimitedYou NVCR | $2.0B | N/A | — | -$1.52 |
 Azenta, Inc. AZTA | $1.1B | N/A | — | -$1.22 |
 BioLife Solutions, Inc. BLFS | $1.3B | N/A | — | -$0.25 |
 Establishment Labs Holdings Inc. ESTA | $2.2B | N/A | — | -$1.72 |
 Evotec SE EVO | $1.0B | N/A | — | -$0.28 |
 Kestra Medical Technologies, Ltd. KMTS | $1.2B | N/A | — | -$2.30 |
 Neogen Corporation NEOG | $2.0B | N/A | — | -$5.03 |
* N/A — Company is not profitable (TTM) · excluded from industry average · ▸ FMP /stock-peers + /ratios?limit=1 · priceToEarningsRatio
Annual PE Ratio History
| Fiscal Year End | PE Ratio | EPS (TTM) | YoY Change | PE vs Max |
|---|---|---|---|---|
2025-12-31Latest FY2025 | — | $-1.22 | — | |
2024-12-31 FY2024 | — | $-1.56 | — | |
2023-12-31 FY2023 | — | $-1.95 | — | |
2022-12-31 FY2022 | — | $-0.88 | — | |
2021-12-31 FY2021 | — | $-0.56 | — | |
2020-12-31 FY2020 | 881.72x | $0.20 | — | |
2019-12-31 FY2019 | — | $-0.07 | — | |
2018-12-31 FY2018 | — | $-0.69 | — | |
2017-12-31 FY2017 | — | $-0.70 | — | |
2016-12-31 FY2016 | — | $-1.54 | — |
▸ FMP /ratios?period=annual&limit=20 · priceToEarningsRatio + netIncomePerShare · Zero extra API
About PE Ratio & Methodology
The price-to-earnings (P/E) ratio for NovoCure Limited (NVCR) measures how much investors pay for each dollar of the company's trailing earnings. NVCR's current PE ratio of N/A is calculated by dividing its stock price of $17.43 by its TTM earnings per share of -$1.52.
Frequently asked questions
NVCR pe ratio · 6 questionsNVCR's current PE ratio is N/A as of 2026-06-08, based on a stock price of $17.43 and TTM EPS of -$1.52. Data sourced from Financial Modeling Prep via NVCR's SEC 10-K and 10-Q filings.
▸ Source: FMP · /ratios-ttm · /ratios annual · /analyst-estimates · /stock-peers · NovoCure Limited SEC 10-K & 10-Q filings · US GAAP · Updated: 2026-06-08